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Abstract
Purpose—To assess the relative radiosensitivities of a large collection of melanoma cell lines
and to determine whether pharmacologic inhibition of mutant B-RAF with PLX-4032 can
radiosensitize B-Raf+ melanoma cells.
Methods and Materials—A large collection of melanoma cell lines (n=37) were treated with 0
– 8 Gy IR and clonogenic survival assays used to generate survival curves to rank relative
radiosensitivities among the cell lines. The ability of a B-RAF inhibitor, PLX-4032, to
radiosensitize highly radioresistant, B-Raf+ cells was also assessed by clonogenic cell survival and
spheroid invasion assays and the effects of treatment on the cell cycle assessed by FACS.
Results—Melanoma cell lines displayed a very large, heterogeneous range of SF2 values (1.002
– 0.053) with a mean of 0.51. Cell lines with surviving fractions of 0.29 or less at SF2 and SF4
were observed at a high frequency of 18.9% and 70.2%, respectively. Treatment of B-Raf+ cells
with the B-RAF inhibitor PLX-4032 in combination with radiation provided enhanced inhibition
of both colony formation and invasion, and radiosensitized cells through an increase in G1 arrest.
Conclusions—Our data suggest that melanomas are not uniformly radioresistant with a
significant subset displaying inherent radiosensitivity. Pharmacologic inhibition of B-RAF with
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PLX-4032 effectively radiosensitized B-Raf+ melanoma cells suggesting this combination
approach could provide improved radiotherapeutic response in B-Raf+ melanoma patients.
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INTRODUCTION
Melanoma represents the sixth most common cancer diagnosed in the U.S. in both men and
women and remains one of the mostly deadly forms of solid malignancies. Importantly,
while overall cancer incidence rates continue to decrease, the incidence of melanoma
continues to rise (1). Remarkably, current treatment options for advanced melanoma beyond
surgical excision have changed little over the last few decades, and adjuvant chemotherapy
provides only short-lived, partial responses in a small subset of patients (2,3).
The role of adjuvant radiotherapy in malignant melanoma remains controversial (4,5). Early
in vitro radiation studies of melanoma cell lines showed wide initial shoulders on survival
curves leading to a widespread belief that melanomas are radioresistant and thus require
high dose per fraction regimens (5–7). These early assessments however have not been
supported by clinical data. A study of 56 melanoma patients that examined locoregional
control after adjuvant radiotherapy found hypofractionation and conventional fractionation
equally efficacious with 5-yr in-field control rates of 87% (8). In the Radiotherapy and
Oncology Group (RTOG) 83-05 prospective study, 137 patients were randomized to receive
either hypofractionation vs conventional fractionation. This study was stopped early when
an interim analysis show no difference between the two arms (complete response rates were
24% vs. 23%, and partial response rates 35% vs. 34%, respectively) (9). More recently, a
randomized trial (TROG 02.01/ANZMTG 01.02) of melanoma patients at high risk of
regional relapse was designed to assess the effect of radiotherapy after lymphadenectomy on
the subsequent risk of regional relapse. Inclusion criteria included ≥1 parotid, ≥2 cervical or
axillary, or ≥3 groin-positive nodes; or extra nodal spread of tumor; or minimum metastatic
node diameter of 3 cm (neck or axilla) or 4 cm (groin). After a median follow-up of 27
months, the risk for local recurrence was significantly elevated in patients who received
lymphadenectomy alone vs. those who received lymphadenectomy followed by adjuvant
radiation (HR=1.77; CI [1.02 – 3.08], P=0.041) (10). While these studies collectively
demonstrate that melanoma is not uniformly radioresistant and that higher dose per fraction
regimens do not improve therapeutic success, the use of radiotherapy as a first-line treatment
in the management of primary melanoma remains uncommon (11,12) and when used, often
incorporates riskier hypofractionation dosing regimens (4). Thus, there is great need not
only to better identify those melanoma patients most likely to respond to radiotherapy and
the optimal dosing regimens that provide the best therapeutic index, but also to discover the
molecular underpinnings that enhance radiosensitivity by identifying novel targets as
radiosensitizers.
Recent discoveries of the molecular aberrancies that promote melanomagenesis have
provided potential new therapeutic targets (13). Mutational activation of the B-RAF serine/
threonine kinase or its upstream activator, N-RAS (a small GTPase), occur at frequencies of
approximately 50% and 15%, respectively, in a mutually exclusive manner and at an early
stage of the disease (14,15). The remaining 35% of melanomas are wild-type (WT) for both
B-Raf and N-Ras (16,17). RAS activation of RAF leads to phosphorylation and activation of
MEK1/2 leading to phosphorylation and activation of ERK1/2 (mitogen-activated protein
kinase; MAPK). Activated ERK1/2 then phosphorylates a number of cytoskeletal proteins,
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kinases, and transcription factors resulting in changes in cell proliferation, differentiation,
apoptosis, invasion, angiogenesis and radioresistance (18–21).
The identification of mutant B-Raf in human cancers in 2002 (14) spawned the development
of several B-RAF inhibitors currently being evaluated as monotherapies in clinical trials of
melanoma (22). One such inhibitor, PLX-4032, recently completed a Phase I trial (23) and is
currently entering into Phase II and III trials. Whether pharmacologic inhibition of B-RAF
can radiosensitize melanoma cells harboring B-Raf mutations is currently unknown.
In this study, we characterized the relative radiosensitivities of a large panel of melanoma
cell lines to begin to study the mechanisms that promote radiosensitivity vs. radioresistance
in melanoma. We also examined whether the B-RAF inhibitor, PLX-4032, selectively
radiosensitizes B-Raf+ melanoma cells.
MATERIALS AND METHODS
Cell lines, reagents and mutational analysis
Cell lines were obtained from the sources indicated (Supple. Table 1) and cultured as
indicated. All cell lines were verified to be mycoplasma-free or, if contaminated, treated
with Plasmocin (InvivoGen) and retested to verify mycoplasma-free status. Genomic DNA
was isolated using Genomic Tips kits (Qiagen), and the mutational status of B-Raf (exons 11
and 15) and N-Ras (codons 12, 13, and 61) determined by direct sequencing of PCR
amplification products as previously described (16). The B-RAF specific inhibitor,
PLX-4032 (provided by Plexxikon Inc/F Hoffmann-La Roche Ltd), was dissolved with
DMSO and stored frozen (< 1 month) at −20°C.
Western blot analyses
Cells were plated in complete media for 24 h and treated with drug or an equal amount of
vehicle control (DMSO) at the times indicated and harvested with lysis buffer as previously
described (18). Proteins (30 μg) were separated over 12% sodium dodecyl sulphate (SDS)/
poly-acrylamide gels and electrophoretically transferred to polyvinyl difluoride (PVDF),
blocked, probed with anti-phospho-ERK1/2 (T202/Y204, #9101) or anti-total ERK1/2
(#9102) (Cell Signaling Technology) followed by the appropriate secondary HRP-
conjugated antibody and visualized by enhanced chemiluminescence (Amersham).
Colony-forming assays (CFA)
Cells were plated in triplicate at low density overnight in complete media, irradiated or
sham-irradiated with the indicated graded, single doses using an RS2000 X-ray Biological
Irradiator (RadSource) and the medium changed 2 h post-irradiation. Briefly, colonies >50
cells were counted approximately 2–3 weeks later, clonogenic surviving fractions were
generated and survival curves fitted to the linear-quadratic model (SF=e−[α * D + β * D2])
using GraphPad Prism 5.0 according to a least squares fit, weighted to minimize the relative
distances squared, and compared using the extra sum-of-squares F test as previously
described (18). Graphs of survival curves for each individual cell line are shown in Supple.
Fig. 1.
For drug treatments, cells were pretreated with DMSO or PLX-4032 at the doses and times
indicated, irradiated at 6 Gy or sham-irradiated, trypsinized and plated at low density with
fresh media without drug and the surviving fraction (SF) [number of colonies formed/
number of cells plated × plating efficiency] calculated from the number of colonies
(minimum of 50 cells/colony) formed in the treated dishes compared with the number
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formed in the non-treated control dishes and significance determined by t-test where
*=P<0.05, **=P<0.01, ***=P<0.001.
Flow Cytometry
Cells were plated and treated as described for the CFA assays with PLX-4032 or DMSO,
sham-irradiated or irradiated at 6 Gy, refed fresh media without drug, and cells harvested 24
h post-irradiation. Cells were collected by trypsinization, fixed in 70% ethanol, resuspended
in 1X PBS containing RNase A (50 μg/ml) and propidium iodide (50 μg/ml) and DNA
content determined by FACS using a Beckman-Coulter CyAn ADP.
Spheroid Invasion Assay
Melanoma spheroids were prepared by the liquid overlay method as described (24). Briefly,
5,000 cells/200 μl growth media/well were added to 96-well plates coated with 100 μl/well
1.5% Noble agar. After 72 h, cell spheroids were collected, treated with PLX-4032 at the
indicated concentrations for 2 h, sham-irradiated or irradiated at 5 Gy, incubated 2 additional
hours, centrifuged and resuspended in a gel (without drug) of bovine collagen I containing
EMEM, Lglutamine, and 2% FBS and replated (4 spheroids/well/condition) in a 24-well
plate placed at 37°C to allow the collagen to solidify. After 72 h of incubation,
photomicrographs of the spheroids were used to calculate the area of invasion of cells that
migrated out from the spheroids into the surrounding collagen using Adobe Acrobat
Professional 9.0 and the invasion fraction determined by comparing the area of invasion of
the drug-treated, irradiated spheroids with the area of invasion of the control non-drug-
treated, unirradiated spheroids. Significance was determined by t-test.
RESULTS
While melanomas as a tumor class are relatively radioresistant, a significant subset do
respond to radiotherapy (10). The molecular underpinnings that drive radioresistance in
melanoma are poorly understood. To begin to uncover these underpinnings, we first
characterized the relative radiosensitivities of a large collection of melanoma cell lines.
Melanoma cell lines show a large, heterogeneous range of radiosensitivities that does not
correlate with mutational status of B-Raf or N-Ras
Our goal was to analyze the radiosensitivities of a collection of melanoma cell lines that
harbored mutations in B-Raf and N-Ras at frequencies seen in patients. Melanoma cell lines
were obtained from several sources, DNA extracted and mutational status of B-Raf and N-
Ras determined (Supple. Table 1). In these melanoma cell lines (n=37), B-Raf and N-Ras
mutations were mutually exclusive, and the frequency of B-Raf+, N-Ras+ and WT (B-Raf
and N-Ras negative) subtypes were 54%, 24%, and 22%, respectively, and thus exhibit
similar frequencies of these genes as seen in the clinic (14–17).
We next determined the relative radiosensitivities among the melanoma cell lines treated
with ionizing radiation (IR) over 0–8 Gy. Supple. Table 1 shows the surviving fractions at 2
Gy (SF2) along with the genotype (B-Raf+, N-Ras+, or WT for B-Raf/N-Ras) for each cell
line. As shown, the melanoma cell lines displayed a very large range of SF2 values ranging
from highly radioresistant to highly radiosensitive (1.002 – 0.053). The mean SF2 value was
0.51 which is similar to those reported for other cancers commonly treated with radiotherapy
such as colon, lung, and breast cancer (25). Cell lines with relatively low surviving fractions
of ≤0.29 at SF2 and SF4 were observed at high frequencies of 18.9% and 70.2%,
respectively (Fig. 1).
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A graph of the survival curves (Fig. 2) showing clonogenic survival after 0–8 Gy revealed
that the cell lines clustered into subgroups of high, medium or low radioresistance. All three
radioresistance subgroups were found in all genotypes (B-Raf+, N-Ras+, or WT for B-Raf/N-
Ras). Interestingly, the frequency of cell lines exhibiting high radioresistance for each
genotype (B-Raf+, N-Ras+, or WT for B-Raf/N-Ras) were 60%, 33%, and 63%, respectively.
While intriguing, these differences did reach statistical significance by Fishers' exact test
(P=0.49).
Inhibition of B-RAF with PLX-4032 radiosensitizes B-Raf+, but not WT or N-Ras+
melanoma cells in colony formation assays
B-RAF is the most common oncogene found in malignant melanoma and many of the highly
radioresistant cell lines were B-Raf+. Several B-RAF inhibitors are currently under clinical
evaluation including PLX-4032 (22). We thus sought to determine whether pharmacologic
inhibition of B-RAF could confer radiosensitization of melanoma cells using colony
formation assays. Four highly or moderately radioresistant B-Raf+ cell lines (SKMel27,
SKMel100, SKMel181, and SKMel28) were pretreated with PLX-4032 prior to irradiation
and surviving fractions compared to cells incubated with DMSO alone. As controls, highly
radioresistant cells genotyped as WT for B-Raf/N-Ras (SKMel131) or N-Ras+ (SKMel119
and VMM39) were also compared, as these should not be radiosensitized by PLX-4032. As
shown in Fig. 3, all B-Raf+ cell lines showed statistically significant radiosensitization by
PLX-4032 with a mean enhancement ratio of 9.7 (range 1.2 – 29.3) at doses that inhibited P-
ERK1/2. In contrast, none of the N-Ras+ or WT cell lines were radiosensitized by PLX-4032
which exhibited a mean enhancement ratio of 0.97 (range 0.8 – 1.1). Survival curves over
multiple doses of radiation are shown in Supple. Fig. 2 and likewise show radiosensitization
B-Raf+, but not N-Ras+ or WT cell lines. Radiosensitization by PLX-4032 was also dose-
dependent. Enhancement ratios for B-Raf+ SK-Mel-27 cells treated with either 1.0, 0.5 or
0.1 μM were 5.7, 2.5, and 1.9, respectively (data not shown). As reported by other groups
for this class of drug, we likewise saw activation of P-ERK1/2 in the N-Ras+ and WT cell
lines which reflects the ability of this drug class to activate c-RAF-1 in non-B-Raf + cells
(26–29).
Radiation in combination with PLX-4032 synergize to block invasion more effectively than
either treatment alone
Activation of the RAF>MEK1/2>ERK1/2 pathway is known to be involved not only with
proliferation and regulation of the cell cycle, but also with promoting motility and invasion
(30,31). To determine whether PLX-4032 could augment the ability of radiation treatment to
block invasion, we utilized the 3D-spheroid collagen invasion assay. Here, the area of
invasion by cells that migrate out from cell spheroids into the surrounding collagen was
measured and the invasion fraction (IF) calculated by comparing the area of invasion of the
treated spheroids relative to control, untreated spheroids. For this experiment we utilized a
B-Raf+ cell line that shows robust growth characteristics in this assay. It should be noted
that this cell line does not grow well at low density and could not be assessed in the colony
formation assay. As shown in Supple. Fig. 3, spheroids of WM2664 cells treated with both
PLX-4032 plus radiation showed a statistically significant greater inhibition (P=0.007) of
cellular invasion in comparison to spheroids treated with PLX-4032 or radiation alone.
Radiosensitization by PLX-4032 is mediated by an increase in G1 arrest
To determine whether PLX-4032-mediated radiosensitization was due, in part, to alterations
in the cell cycle distribution, two B-Raf+ cell lines (SKMel100 and WM2664) and one N-
Ras+ line (VMM39) were pretreated with PLX-4032 with or without radiation as in Fig.3,
and analyzed by flow cytometry 24 h post-irradiation. As shown in Fig. 4, both B-Raf+ cell
lines showed an increase in G1 arrest when treated with PLX-4032 + radiation in
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comparison to radiation or drug alone and control, untreated cells. In contrast, the control N-
Ras+ line showed no enhanced G1 arrest when treated with PLX-4032 + radiation relative to
control, untreated cells.
DISCUSSION
Our studies showed that melanoma cell lines display a very wide, heterogeneous range of
radiosensitivities including not only radioresistant phenotypes, but also a radiosensitive
phenotype which was observed in a significant number of cell lines. Comparisons of relative
radiosensitivities among cells with genotypes of B-Raf+, N-Ras+ and WT for B-Raf/N-Ras
suggested that while cells with genotypes of B-Raf+ and WT for B-Raf/N-Ras were more
likely to be highly radioresistant than N-Ras+ cell lines, this difference did not reach
statistical significance. Pharmacologic inhibition of B-RAF with PLX-4032 effectively
radiosensitized B-Raf+ cells both by colony formation and invasion assays and was
associated with enhancement of G1 arrest.
Previous in vitro studies with smaller numbers of melanoma cell lines also showed wide,
heterogeneous ranges of radiosensitivities (32–34). Amundson et.al. recently analyzed the
relative radiosensitivities of the NCI 60 panel of cancer cell lines and showed a similar
heterogeneous range of radiosensitivities for several cancer subtypes often treated with
adjuvant radiotherapy including those of the breast, colon and lung which exhibited similar
average SF2 values (breast; 0.47, colon 0.52, lung; 0.54) (25). This study also included an
analysis of 10 melanoma cell lines which showed an average SF2 of 0.58 and a range of
radiosensitivity between 0.18 – 0.95 at SF2. Our analyses of 37 melanoma cell lines also
showed similar values with an average of 0.51 and a larger range of radiosensitivities
between 0.053 – 1.002 at SF2. In contrast, the percentage of melanoma cell lines exhibiting
SF2 values ≤0.29 were found in only 1/10 (10%) of the cell lines examined in the
Amundson study while in our study we found 7/37 (18.9%) of the lines to be sensitive (25).
The differences between these studies are likely due to the sample size (n=10 vs. n=37).
Thus, our study shows that while a majority (81%) of melanoma cells exhibit an intrinsic
resistance to radiation, a significant percentage (19%) show an intrinsic sensitivity to
radiation suggesting that this group of melanomas would be good candidates for
radiotherapeutic control of local recurrence. In addition, melanoma cells exhibit
radiosensitivity profiles similar to that of other carcinomas often treated with radiotherapy
suggesting melanoma is not uniformly radioresistant. This is a concept supported not only
by the early results of the TROG 02.01/ANZMTG 01.02 trial (10), but also by the use of
radiotherapy in the management of melanoma brain metastases where local control rates
range from about 50–85% with reported complete response rates of 14% (35–38). Critical to
the treatment of the radioresistant melanomas will be the development of new and improved
radiotherapeutic approaches, which will require a better understanding of the molecular
pathways that drive radioresistance. The identification of these pathways could potentially
be expose novel targets to radiosensitize melanoma. Future analyses of our collection of
melanoma cell lines should provide the foundation to identify such molecular mechanisms
of radioresistance leading to the discovery of novel radiosensitizers in melanoma.
Previous studies in both rodent and human cells have shown that activation of RAS and
RAF promote radioresistance (21,39,40). In addition, in EGFR or HER2 positive breast
cancer cells, blockade of MEK1/2>ERK1/2 signaling by pharmacologic inhibition of MEKI
caused radiosensitization while expression of constitutively active RAF promoted
radioresistance (18). These studies demonstrated that activation MEK1/2>ERK1/2 either by
direct mutational activation of Ras or Raf or by indirect activation through upstream
activators such as EGFR/HER2 results in promotion of radioresistance. While not
statistically significant, our data suggest radioresistance might correlate more with B-Raf+ or
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B-Raf/N-Ras WT than Ras+ cells. Analyses with a larger number of WT and Ras+ cells
would be required to statistically power these comparisons.
Biologic modulation of the radiation response involves the use of radiosensitizers that target
signaling pathways resulting in enhanced loss of reproductive integrity or cell death.
Preclinical studies using a variety of EGFR inhibitors in different model systems have
shown their substantial promise as radiosensitizers (41). Cetuximab (Erbitux, ImClone
Systems, Inc), a monoclonal antibody targeting EGFR, was the first biologic agent to show
local control and survival advantage when used as a radiosensitizer in patients with head and
neck cancer (42).
Metastatic melanoma has high propensity for both locoregional recurrence and distant
metastasis and is a particularly difficult cancer to treat due to the limited systemic
chemotherapeutic treatment options for this cancer. PLX-4032 is a novel, small-molecule B-
RAF kinase inhibitor previously shown to inhibit P-ERK1/2 levels and growth of B-Raf+
melanoma cell lines (24). Importantly, results from a phase I trial of PLX-4032 showed
tumor regression in 81% (26/32) of B-Raf+ melanoma patients treated at the MTD (23). Our
studies showed that pretreatment of several B-Raf+ melanoma cell lines, including some of
our most radioresistant lines, were effectively radiosensitized with PLX-4032 in both colony
formation assays (average ER=8.1) and invasion assays through increased arrest in G1. The
clinical relevance of our findings are important given that melanoma brain metastases are
often treated with radiotherapy and that a similar B-Raf inhibitor developed by
GlaxoSmithKline (GSK2118436) currently under clinical evaluation as a monotherapy has
been reported in preliminary analyses to reduce the size of melanoma brain metastases in B-
Raf+ patients (43). Interestingly, SK-Mel-28, despite being fairly resistant to PLX-4032
treatment alone, was slightly radiosensitized. The molecular mechanisms responsible for
drug resistance to PLX-4032 in patients remains to be determined. SK-Mel-28 cells could
provide an in vitro model to study this resistance.
In summary our data suggest that melanomas are not uniformly radioresistant, that a
significant subset of melanomas are inherently radiosensitive and that inhibition of B-RAF
with PLX-4032 effectively radiosensitizes B-Raf+ melanoma cells. This suggests that
PLX-4032 or other B-RAF inhibitors in combination with radiation could provide improved
radiotherapeutic response in B-Raf+ melanomas. Our study supports future clinical trials to
evaluate the ability of PLX-4032 or similar pharmaceuticals that target BRAF to
radiosensitize B-Raf+ melanomas.
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Refer to Web version on PubMed Central for supplementary material.
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FIG. 1. A significant subset of melanoma cell lines are radiosensitive
The percentage of cell lines with surviving fractions in the ranges indicated are shown for
SF2 and SF4. A significant number of lines are radiosensitive with surviving fractions of
0.29 or less at SF2 and SF4 seen in 18.9 % and 70.2 %, respectively, of the cell lines.
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FIG. 2. Melanoma survival curves
(A) Survival curves over 0–8 Gy were generated for 37 melanoma all cell lines and relative
radioresistance subgrouped as low ( ), medium ( ), or high ( ). (B) Statistical
comparisons of relative radioresistance among B-Raf+, N-Ras+, or BRaf/N-Ras WT
melanoma cell lines. Fisher's exact test showed no significant differences between genotypes
(P=0.49).
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FIG. 3. PLX-4032 radiosensitizes B-Raf+ melanoma cells
(A) B-Raf+ cells (SKMel27, SKMel100, SK-Mel-181, SK-Mel-28) were fed fresh media
containing DMSO or PLX-4032 for 48 h at the indicated concentrations to achieve partial
inhibition with drug alone, irradiated at 6 Gy, trypsinized 2 hr post-irradiation and replated
as single cells and colonies stained and counted after 2–3 weeks incubation. Surviving
fractions were calculated by comparison to DMSO control cells. Control B-Raf/N-Ras WT
(SKMel131) and N-Ras+ (SKMel119 and VMM39) cells were pretreated similarly with the
highest dose of PLX-4032 (10.0 μM). (B) Enhancement ratios (ER) = SF radiation alone/
PLX-4032 + radiation. (C) Protein lysates were collected from cells treated with PLX-4032
for 48 h at the concentrations described in (A) and western blot analyses performed with
anti-pERK1/2 or anti-ERK1/2 as a loading control to show the levels of pERK1/2 at the time
of radiation.
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FIG. 4. Radiosensitization by PLX-4032 correlates with an increase of cells in G1
Melanoma cells were pretreated with PLX-4032 (as in Fig. 3) or DMSO for 48 h, cells
irradiated with 6 Gy or sham-irradiated, and DNA content assessed by FACS analyses 24 h
post-irradiation. Shown are percentages of cells in each stage of the cell cycle.
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